The bivalent cervical cancer vaccine is suitable for women aged 9-45 years to prevent HPV type 16 and 18 infection and reduce the incidence of cervical cancer and precancerous lesions caused by these two viruses, and is a self-funded vaccine. The vaccine is administered intramuscularly in three doses, with a one-month interval between the first and second doses and a five-month interval between the second and third doses, taking six months to complete. However, there are certain contraindications to the bivalent cervical cancer vaccine, such as those who are allergic to the ingredients contained in the vaccine are prohibited; those who are in acute illness, such as high fever or cold, should not be vaccinated and should wait for their recovery; pregnant women are also not recommended to receive the vaccine, but if they are found to be pregnant after receiving the vaccine, these people should not worry too much and do not need to terminate their pregnancy. In addition, similar to other vaccines, the bivalent cervical cancer vaccine may cause adverse reactions, including redness, swelling, pain, dizziness, nausea and fatigue at the injection site, but the symptoms are generally mild and can be relieved after rest. The bivalent cervical cancer vaccine is safe, but it is important to understand that the vaccine is not a substitute for all screenings, and patients who have been vaccinated still need to go to the hospital for regular screenings.